A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19
- Alfred H.J. Kim,
- Jeffrey A. Sparks,
- Jean W. Liew,
- Michael S. Putman,
- Francis Berenbaum,
- Alí Duarte-García
- Washington University School of Medicine in St. Louis,
- Harvard Medical School,
- University of Washington,
- Northwestern Medicine,
- Sorbonne University,
- Mayo Clinic
Research Output:
Contribution to journal
Comment/debate
Open access
Publication Information
Output type
Research Output:
Contribution to journal
Comment/debate
Original language
EnglishPages from-to (Number of pages)
Pages 819-821 (3 pages)Journal (Volume, Issue Number)
Annals of internal medicine (Volume 172, Issue 12)Publication milestones
- Published - 16/06/2020
Publication status
Published - 16/06/2020
ISSN
0003-4819Publication IDs
- Scopus: 85083710801
- PubMed: 32227189
Funding Details
Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.
FundersFunding numbers
National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence
-NIH
-NIAMS
U54 AR057319, P30AR070253
GSK
-Gilead Sciences
-NCATS
-VF
-VCRC
-Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Captures
407
Social media
27
Mentions
4
Citations
173